Previous close | 217.50 |
Open | 202.40 |
Bid | 0.00 x N/A |
Ask | 216.60 x N/A |
Day's range | 202.40 - 202.40 |
52-week range | 178.90 - 272.40 |
Volume | |
Avg. volume | 2 |
Market cap | N/A |
Beta (5Y monthly) | -0.02 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 23 Jul 2024 - 29 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
An FDA panel voted unanimously to support Eli Lilly's Alzheimer's drug for use in adults 60-85 years old.
TOKYO and CAMBRIDGE, Mass., June 09, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. A Prescription Drug Us
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.